Minnesota Eye Consultants Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2006
NCT00405457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Minnesota Eye Consultants, P.A.

Active Ingredients

Drugs in Phase 4 Trials (2)

bepotastine (bepreve) (1 trial)

cyclosporine (sandimmune) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 4)

Dry Eye Syndromes (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2